Singh Utpal Kant, Prasad Rajniti, Kumar Ranjeet, Jaiswal Bir Prasad
Department of Pediatrics, Nalanda Medical College, Patna 800 020, India.
Indian Pediatr. 2006 Dec;43(12):1076-80.
Sixty four children (38 boys and 26 girls), aged 1 yr to 14 yr, presenting with fever, splenomegaly and positive LD body in splenic smear examination, admitted to pediatric ward of Nalanda Medical college and Child care center between 1st July 03 to 30th June 04 were taken for study. Patients were categorized into two groups: 44 were in Group I (Patients who had not received prior antileishmanial drug) and 20 in Group II (Patients who had received 30 days course of SAG; 20 mg per kg per day). All patients were given Miltefosine in dose of 2.5 per kg per day od or bid per orally to a maximum of 100 mg and were followed at completion of therapy, 1 month and 6 months for clinical response, splenic size and parasite density. 63 patients had parasitological cure with relapse in one patient of Group I during follow up. One patient in Group II had no response with first course but became parasitologically negative with 2nd course of Miltefosine. In Group I, one patient had persistent splenomegaly and found to have associated portal hypertension. GI side effects i.e. diarrhea and vomiting were observed in 26 and 23 patients respectively. Majority of patients had pancytopenia. Elevated ALT (> 3 times of normal) were seen in 28 and 11 patients of Group I and Group II respectively which returned to normal in subsequent follow up. The final cure rates were 93.2 percent and 95 percent in Groups I and II respectively.
2003年7月1日至2004年6月30日期间,64名年龄在1岁至14岁之间、出现发热、脾肿大且脾涂片检查发现利杜体阳性的儿童被收治于那烂陀医学院儿科病房及儿童保健中心进行研究。患者被分为两组:44名在第一组(未接受过抗利什曼原虫药物治疗的患者),20名在第二组(接受过30天疗程的SAG治疗,每天每公斤体重20毫克)。所有患者均按每天每公斤体重2.5毫克的剂量口服米替福新,每日一次或两次,最大剂量为100毫克,并在治疗结束时、1个月和6个月时进行随访,观察临床反应、脾脏大小和寄生虫密度。63名患者实现了寄生虫学治愈,第一组有一名患者在随访期间复发。第二组有一名患者第一疗程无反应,但第二疗程米替福新治疗后寄生虫学转为阴性。在第一组中,有一名患者持续脾肿大,发现伴有门静脉高压。分别有26名和23名患者出现胃肠道副作用,即腹泻和呕吐。大多数患者出现全血细胞减少。第一组和第二组分别有28名和11名患者谷丙转氨酶升高(>正常上限3倍),在随后的随访中恢复正常。第一组和第二组的最终治愈率分别为93.2%和95%。